PT-141 vs Melanotan II: Melanocortin Peptide Comparison for Sexual Health Research | Peptpedia

PT-141 (Bremelanotide) completed the full drug development pathway. After initial development as a potential tanning agent and a Phase 3 program for sexual dysfunction, the FDA approved Bremelanotide (Vyleesi) in June 2019 specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. This makes it the second FDA-approved treatment for HSDD (after flibanserin/Addyi). The approved product is an auto-injector for subcutaneous administration as needed, not more than once per 24 hours.

Melanotan II has never been evaluated in formal human clinical trials and has no regulatory approval in any country. It has been available through research chemical suppliers and has been widely self-administered, generating a substantial body of anecdotal and observational data but no controlled safety or efficacy evidence.

PT-141 (Bremelanotide) incorporates a cyclic lactam bridge structure engineered to preferentially activate MC3R and MC4R with minimal MC1R affinity. MC4R activation in the hypothalamus and medial preoptic area drives sexual arousal through dopaminergic signaling cascades, operating independently of the vascular mechanisms used by PDE5 inhibitors such as sildenafil. This central mechanism of action distinguishes PT-141 from all other FDA-approved treatments for sexual dysfunction, which act peripherally on vascular smooth muscle or modulate serotonergic neurotransmission.

Melanotan II exhibits broader melanocortin activation spanning multiple receptor subtypes:

• MC1R (melanogenesis): Drives melanocyte stimulation and the characteristic tanning effect, but also promotes melanocyte proliferation
• MC3R and MC4R (appetite/sexual function): Produces the sexual arousal and appetite-suppressing effects shared with PT-141
• MC5R (sebaceous gland regulation): Modulates exocrine gland secretion with poorly characterized systemic effects

Both compounds are cyclic heptapeptide analogs of alpha-MSH, sharing the core His-Phe-Arg-Trp pharmacophore essential for melanocortin receptor binding. The structural divergence lies in PT-141's lactam bridge, which constrains the peptide backbone conformation in a manner that confers MC4R selectivity over MC1R. This selectivity difference is the pharmacological basis for PT-141's clinical utility as a sexual function agent without tanning side effects.

Melanotan II MC1R activation carries documented dermatological risks. Reid and Fitzgerald (2013) reported cases of atypical melanocytic naevi developing within days of Melanotan II administration, with new mole formation and changes to existing naevi observed across multiple case reports. MC1R activation drives melanocyte proliferation through the same signaling pathway implicated in melanoma development. No long-term controlled studies exist to characterize the magnitude of this dermatological risk, and the absence of standardized dosing further complicates risk assessment.

PT-141 has a well-characterized safety profile from its Phase 3 RECONNECT trials and post-marketing surveillance. The FDA label includes:

• Transient blood pressure elevation: 10-15 mmHg systolic increase, MC4R-mediated sympathetic activation, typically resolving within 12 hours
• Nausea: Reported in approximately 40% of patients, the most common treatment-related adverse event
• Flushing and headache: MC4R-mediated vasomotor effects in a minority of patients
• No significant MC1R-driven dermatological effects: Consistent with PT-141's poor MC1R affinity demonstrated in receptor binding assays

Neither compound carries regulatory approval for cosmetic use. Melanotan II has no established human safety profile from controlled trials, no standardized manufacturing, and no pharmacovigilance data. PT-141's safety data derives from trials enrolling over 1,200 patients with systematic adverse event monitoring.

PT-141 is the only melanocortin peptide with FDA approval for any indication. The RECONNECT Phase 3 program enrolled over 1,200 premenopausal women with hypoactive sexual desire disorder across two randomized, double-blind, placebo-controlled trials, demonstrating statistically significant improvements in sexual desire and reductions in associated distress. This evidence base makes PT-141 the reference compound for melanocortin-mediated sexual function research.

Melanotan II lacks any completed randomized controlled trial in humans. All available human evidence is observational, anecdotal, or derived from case reports. The compound's primary research interest lies in its MC1R-driven melanogenesis effects, which PT-141 does not produce due to its engineered receptor selectivity.

For sexual function research, PT-141 provides the evidence-based reference compound with established dose-response data, safety parameters, and regulatory validation. For melanogenesis research, Melanotan II remains the only melanocortin peptide with strong MC1R tanning effects, but the absence of controlled safety data and the documented association with atypical melanocytic naevi limit its research utility. Researchers investigating melanocortin receptor pharmacology across subtypes may find both compounds informative as complementary tools with different selectivity profiles.

FDA Drug Label: Vyleesi (bremelanotide) prescribing information via NIH DailyMed.